ERBB2 and breast carcinoma: Moreover, an adjunct study evaluated circulating miR-21, miR-210, and miR-373 using qRT-PCR in the serum samples of 127 HER2+ breast cancer patients from Geparquinto trial before and after neoadjuvant therapy and 19 healthy controls and demonstrated changes in serum miR-21, miR-210, and miR-373 before and after treatment30.